CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP) have been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $8.3571.

A number of research firms have weighed in on CAMP. Leerink Partners boosted their target price on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, April 2nd. Chardan Capital set a $6.50 price objective on CAMP4 Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Weiss Ratings downgraded CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Finally, Zacks Research lowered CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday.

CAMP4 Therapeutics Trading Down 7.4%

Shares of CAMP4 Therapeutics stock opened at $3.90 on Friday. The firm has a fifty day simple moving average of $4.28 and a 200-day simple moving average of $4.56. CAMP4 Therapeutics has a 1-year low of $1.32 and a 1-year high of $7.75. The stock has a market capitalization of $202.53 million, a price-to-earnings ratio of -1.65 and a beta of 0.10.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%.The firm had revenue of $1.29 million for the quarter. As a group, research analysts predict that CAMP4 Therapeutics will post -0.84 earnings per share for the current year.

Hedge Funds Weigh In On CAMP4 Therapeutics

Several large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new stake in CAMP4 Therapeutics in the 4th quarter valued at $61,000. Jefferies Financial Group Inc. acquired a new position in shares of CAMP4 Therapeutics during the fourth quarter valued at about $70,000. State Street Corp lifted its stake in shares of CAMP4 Therapeutics by 52.7% in the fourth quarter. State Street Corp now owns 39,700 shares of the Wireless communications provider’s stock valued at $243,000 after buying an additional 13,700 shares during the period. Bank of America Corp DE acquired a new stake in CAMP4 Therapeutics during the fourth quarter worth about $86,000. Finally, OMERS ADMINISTRATION Corp bought a new position in CAMP4 Therapeutics during the fourth quarter valued at about $115,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.